P1.01-09 Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC With PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.565
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PD.1.01 Health-Related Quality of Life With Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA04.05 Outcomes in NSCLC Patients Treated With First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.04-24 EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC With PD-L1 ≥50%, a Phase 3 Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-16 First-Line Pembrolizumab With or Without Chemotherapy in PD-L1 Positive NSCLC: A Network Meta-Analysis of Randomized Trials

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-106 Pembrolizumab Randomized, Phase 1 Study in Chinese Patients With Advanced NSCLC: KEYNOTE-032

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.04-26 EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC With PD-L1 <50%

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA10.08 Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-Line (1L) Treatment of Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.04-25 EMPOWER-Lung 3: A Phase 3 Study of Cemiplimab, Ipilimumab and Chemotherapy in Advanced NSCLC With PD-L1 <50%

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy